Dyadic International (DYAI) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 60.7% versus a loss of 85.3%. Dyadic International is the larger company by market cap ($17.8 million vs $16.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | RADX |
|---|---|---|
| Share price | $0.4444 | $1.11 |
| Market cap | $17.80M | $16.20M |
| 1-day change | -2.65% | -3.48% |
| YTD return | -52.72% | -78.74% |
| 1-year return | -60.67% | -85.27% |
| 5-year return | -90.84% | — |
| EPS (TTM) | $-0.23 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $16.25 |
| 52-week low | $0.34 | $1.00 |
| Distance from 52-week high | -72.23% | -93.17% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1137.62% | +1430.63% |
| Average volume | 201.91K | 84.72K |
| Shares outstanding | 40.06M | 14.59M |
| Employees | 5 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed RADX by 24.6 percentage points over the past year.
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
DYAI vs RADX FAQ
Which is bigger, Dyadic International or Radiopharm Theranostics?
Dyadic International (DYAI) is larger, with a market capitalization of $17.80M compared with $16.20M for Radiopharm Theranostics (RADX).
Which stock has performed better over the past year, DYAI or RADX?
DYAI returned -60.67% over the past 12 months, compared with -85.27% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Radiopharm Theranostics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Dyadic International and Biotechnology: Pharmaceutical Preparations for Radiopharm Theranostics.